Croxford J Ludovic, Pryce Gareth, Jackson Samuel J, Ledent Catherine, Giovannoni Gavin, Pertwee Roger G, Yamamura Takashi, Baker David
Department of Neuroinflammation, Institute of Neurology, University College London, London WC1N 1PJ, United Kingdom.
J Neuroimmunol. 2008 Jan;193(1-2):120-9. doi: 10.1016/j.jneuroim.2007.10.024. Epub 2007 Nov 26.
Cannabinoids may exhibit symptom control in multiple sclerosis (MS). We show here that cannabinoid receptor (CBR) agonists can also be immunosuppressive and neuroprotective in models of MS. Immunosuppression was associated with reduced: myelin-specific T cell responses; central nervous system infiltration and reduced clinical disease. This was found to be largely CB(1)R-dependent and only occurred at doses that induced significant cannabimimetic effects that would not be achieved clinically. Lower, non-immunosuppressive doses of cannabinoids however, slowed the accumulation of nerve loss and disability, despite failing to inhibit relapses. This further highlights the neuroprotective potential of cannabinoids to slow the progression of MS.
大麻素可能对多发性硬化症（MS）有症状控制作用。我们在此表明，大麻素受体（CBR）激动剂在MS模型中也具有免疫抑制和神经保护作用。免疫抑制与以下方面的降低有关：髓鞘特异性T细胞反应；中枢神经系统浸润以及临床疾病减轻。发现这在很大程度上依赖于CB(1)R，并且仅在诱导出显著拟大麻效应的剂量下才会发生，而这种剂量在临床上是无法达到的。然而，较低的、无免疫抑制作用的大麻素剂量，尽管未能抑制复发，但减缓了神经损伤和残疾的累积。这进一步凸显了大麻素减缓MS进展的神经保护潜力。
